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Stroke after Alzheimer disease I have more bad news A rather dark joke has it that a doctor is speaking with his patient, Mr. Jones, after examining him.
"I have bad news, Mr. Jones. You have cancer." "My goodness, cancer, that's awful," says the shocked and saddened patient.
"I don't know how to say this," continues the grave doctor, "but I have more bad news. You also have Alzheimer disease."
"Oh no, oh no, Alzheimer disease, that's terrible!" Mr. Jones replies. He then rallies his spirits. "Well, I need to look at the bright side. Things could be worse. At least I don't have cancer."
With this bit of medical humor in mind, we read the current report from Chi et al. 1 that patients diagnosed with Alzheimer disease (AD) are at increased risk of incident stroke. These results come from analysis of Taiwan's population-based National Health Insurance Research Database, containing 1 million randomly sampled beneficiaries of Taiwan's National Health Insurance program. A case group of 980 individuals with AD were selected by a reasonable diagnostic surrogate: their use of an acetylcholinesterase inhibitor, a drug class that is restricted in Taiwan to individuals meeting criteria for probable mild to moderate AD and that is not reimbursed for use in vascular or mixed dementia. Each AD patient was matched to 5 non-AD individuals, selected by similarity on a propensity score that included demographic and medical factors related to the AD diagnosis. Over an average of approximately 4 person-years of follow-up, ischemic and hemorrhagic strokes occurred with incidence rates of 37.8 and 5.2 per 1,000 person-years in AD vs 23.2 and 3.0 in non-AD controls, yielding adjusted hazard ratios of 1.67 (95% confidence interval [CI] 1.37-2.01) for ischemic stroke and 1.70 (95% CI 1.03-2.79) for hemorrhagic stroke. Cancer, conversely, occurred with similar incidence in the 2 groups (adjusted hazard ratio 1.13, 95% CI 0.71-1.80).
An analysis such as this of a population-derived database offers both the strengths and the weaknesses of an aerial photograph: a comprehensive, unbiased view of an entire population, but without the granular patient-by-patient detail that permits a full understanding of the data. The authors have used the best available approaches to limit their cases to pure rather than mixed AD, but as they note, this group may still have included individuals with small infarcts not clearly related to their dementia. The use of propensity score matching, a well-established method for minimizing differences associated with a particular exposure (AD here), is another helpful approach for reducing systematic bias. It is nonetheless difficult to know whether the patients with AD tended to have more severe vascular risk factors (such as hypertension, diabetes, or dyslipidemia), less intensive risk factor control, or more careful ascertainment of incident stroke than the non-AD individuals. Finally, it is important to note that data from Asian populations, which tend to report relatively high rates of vascular dementia, 2 may not be readily generalizable to non-Asian populations. These caveats notwithstanding, the authors are to be commended for their rigorous and creative analysis.
How then should the clinician caring for patients with AD interpret these results? The most straightforward explanation, that AD actually causes stroke, appears unlikely. AD is a complex and still incompletely understood process, 3 but has not been implicated on its own as a cause of vascular disease. The more plausible scenario is that AD and stroke share vascular disease-small-vessel disease of the brain in particular-as a common underlying pathogenic risk. By this line of reasoning, individuals in the AD group were more likely to have underlying cerebrovascular disease, contributing first to their diagnosis of dementia and subsequently to their incident stroke.
This interpretation is supported by the growing literature that small, apparently silent infarcts detected by MRI in healthy elderly individuals confer substantial risk for both incident ischemic stroke 4 and dementia. 5 These small infarcts likely mark the presence of advanced smallvessel disease and are accompanied by other, more numerous lesions such as cerebral microbleeds 6 and microinfarcts. 7 The cumulative effect of these smallvessel-related injuries seems to be to lower the threshold for dementia, such that lesser amounts of AD pathology are sufficient to trigger clinical impairment. 8 This body of literature would predict that the AD cases in the current study had greater burdens of small-vessel disease than the non-AD controls and were at accordingly increased risk of future symptomatic stroke. An additional factor at play in the increased risk for incident hemorrhagic stroke is the biological association of AD with cerebral amyloid angiopathy, a small-vessel process specifically linked to intracerebral hemorrhage. 9 The study by Chi et al. provides good motivation for clinicians to focus on control of vascular risk factors in all patients with dementia. Even if AD itself does not cause stroke, the current data suggest it may be a reasonably strong marker for future stroke and thus identify an at-risk population for intervention. More broadly, the study supports the concept that dementia is more often a result of multiple, mixed pathologies rather than a single process such as AD. 10 This may be seen as bad news, because mixed processes can be difficult to unravel and elucidate. Conversely, each contributor to dementia represents a fresh target potentially amenable to future treatment and prevention strategies. As Mr. Jones says, we should look at the bright side.
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